Tailored therapeutic approaches in acute myeloid leukaemia

被引:0
作者
Kayser S. [1 ]
Schlenk R.F. [1 ]
机构
[1] Department of Internal Medicine III, University Hospital of Ulm, 89081 Ulm
关键词
Acute myeloid leukaemia; ATRA; FLT3-ITD; NPM1;
D O I
10.1007/s12254-009-0095-9
中图分类号
学科分类号
摘要
PURPOSE OF REVIEW: In recent years new molecular markers have emerged as significant prognostic parameters and as potential targets for molecularly targeted therapy in acute myeloid leukaemia (AML). Prognostic markers, however, cannot guide the decision for a specific treatment since they are associated with a differential outcome regardless of the given treatment. In contrast, predictive markers indicate a treatment benefit in patients that are characterized through these markers. Thus predictive markers can guide clinical decision-making. RECENT FINDINGS: In young adults mutations of the NPM1 (NPM1 mut) gene in the absence of concurrent FLT3-ITD (FLT3-ITD neg) mutations have impressive prognostic and beyond prognostication also predictive properties. This NPM1 mut/FLT3-ITDneg genotype predicts equivalent favourable outcome after intensive chemotherapy and allogeneic stem cell transplantation, whereas in the absence of this marker clinical outcome was significantly improved after an allogeneic transplantation. In addition, within a retrospective study performed in older adults the same genotype predicted a significantly improved outcome if all-trans retinoic acid was added to intensive chemotherapy. SUMMARY: The discovery of new prognostic and predictive markers has increased our understanding of leukaemogenesis thus leading to an improved prognostication. Furthermore, current clinical research focusing on the assessment of genotype-specific therapy may translate into an increase in the cure rate. © 2009 Springer-Verlag.
引用
收藏
页码:18 / 21
页数:3
相关论文
共 30 条
  • [1] Gilliland D.G., Jordan C.T., Felix C.A., The molecular basis of leukemia, Hematology Am Soc Hematol Educ Program, pp. 80-97, (2004)
  • [2] Grimwade D., Walker H., Oliver F., Et al., The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. the Medical Research Council Adult and Children's Leukaemia Working Parties, Blood, 92, pp. 2322-2333, (1998)
  • [3] Byrd J.C., Mrozek K., Dodge R.K., Et al., Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461), Blood, 100, pp. 4325-4336, (2002)
  • [4] Frohling S., Schlenk R.F., Kayser S., Et al., Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from AMLSG trial AML HD98-B, Blood, 108, pp. 3280-3288, (2006)
  • [5] Kelly L.M., Liu Q., Kutok J.L., Et al., FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model, Blood, 99, pp. 310-318, (2002)
  • [6] Schlenk R.F., Dohner K., Krauter J., Et al., Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia, N Engl J Med, 358, pp. 1909-1918, (2008)
  • [7] Falini B., Mecucci C., Tiacci E., Et al., Gimema Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype, N Engl J Med, 352, pp. 254-266, (2005)
  • [8] Grisendi S., Mecucci C., Falini B., Et al., Nucleophosmin and cancer, Nat Rev, 6, pp. 493-505, (2006)
  • [9] Thiede C., Koch S., Creutzig E., Et al., Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML), Blood, 107, pp. 4011-4020, (2006)
  • [10] Dohner K., Schlenk R.F., Habdank M., Et al., Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations, Blood, 106, pp. 3740-3746, (2005)